New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
19:03 EDTSCRApexigen announces initiation of clinical trials by its partner, Simcere Pharma
Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced that its partner, Simcere Pharmaceutical Group of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen's proprietary antibody technology platform to enter human trials.
News For SCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SCR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use